UBS Group
TARO

UBS Group’s Taro Pharmaceutical Industries Ltd. TARO Stock Holding History

UBS Group’s Portfolio TARO Stock Details TARO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-200
Closed -$30K – 9507
2014
Q4 		$30K Buy
+200
New +$29.4K ﹤0.01% 7120

Other funds holding TARO

KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
AIIMS
Analyst IMS Investment Management Services Tel-Aviv, Israel $3.3B AUM 20.27% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
LI
LRI Investments Palm Beach Gardens, Florida $1.24B AUM 11.13% 1-Year Est. Return
GCM
Gladius Capital Management Chicago, Illinois $2.24B AUM 23.45% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
LC
Lindbrook Capital Calabasas, California $1.08B AUM 10.14% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return
Carson Wealth (CWM LLC)
Carson Wealth (CWM LLC) Omaha, Nebraska $38.1B AUM 19.66% 1-Year Est. Return

UBS Group's TARO Position: Q2 2024 in Review

UBS Group sold out of Taro Pharmaceutical Industries Ltd. (TARO) in Q2 2024, closing a stake of 31,317 shares — an estimated $1.33M sold.

UBS Group first reported a position in TARO in Q4 2014 and held it in 38 quarters. The position peaked at $3.74M in Q3 2020. 16 funds tracked by Wall St. Rank hold TARO as of Q2 2024.

  • UBS Group reported no remaining Taro Pharmaceutical Industries Ltd. position as of Q2 2024 after selling out during the quarter.
  • UBS Group sold 31,317 Taro Pharmaceutical Industries Ltd. shares in Q2 2024, an estimated $1.33M.
  • UBS Group first reported a position in Taro Pharmaceutical Industries Ltd. in Q4 2014 and held it in 38 quarters.
  • UBS Group's Taro Pharmaceutical Industries Ltd. position peaked at $3.74M in Q3 2020.
  • 16 funds tracked by Wall St. Rank held Taro Pharmaceutical Industries Ltd. as of Q2 2024.

Based on UBS Group's 13F filing for Q2 2024, filed 14 Aug 2024.